Idenix Pharmaceuticals Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

April 2024 | 50 pages | ID: I96E8F15EF2BEN
BAC Reports

Abstracts

Idenix Pharmaceuticals Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Idenix Pharmaceuticals Inc. and its competitors. This provides our Clients with a clear understanding of Idenix Pharmaceuticals Inc. position in the Pharmaceuticals and Biotechnology Industry.

• The report contains detailed information about Idenix Pharmaceuticals Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• Another part of the report is a SWOT-analysis carried out for Idenix Pharmaceuticals Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
• The Idenix Pharmaceuticals Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
• In the part that describes Idenix Pharmaceuticals Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Idenix Pharmaceuticals Inc. business.

About Idenix Pharmaceuticals Inc.

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The company's primary research and development focus is on the treatment of hepatitis C virus (HCV).

Products and Drug Candidates

The company’s HCV discovery program is focused on multiple classes of drugs, which include nucleoside/nucleotide polymerase inhibitors, non-nucleoside polymerase inhibitors, protease inhibitors and NS5A inhibitors:

Nucleoside/Nucleotide Polymerase Inhibitors

The company's advanced development program is its next-generation nucleoside/nucleotide polymerase inhibitor, IDX184, a liver-targeted nucleotide prodrug candidate that enables the delivery of nucleoside monophosphate to the liver. In October 2009, it initiated a 14-day dose-ranging phase IIa clinical trial evaluating IDX184 in combination with pegylated interferon and ribavirin in treatment-naive HCV genotype 1 infected patients. This clinical trial is ongoing.

Non-Nucleoside Polymerase Inhibitors

The company’s primary drug candidate for its non-nucleoside inhibitor program is IDX375, a palm-binding polymerase inhibitor. In September 2009, the company submitted a clinical trial application (CTA) for a choline salt form of IDX375. In November 2009, the company initiated a single ascending dose phase I clinical study in healthy volunteers, in which IDX375 exhibited favorable safety and pharmacokinetics properties. It also submitted a CTA for a free acid form of IDX375.

Protease Inhibitors

The company selected IDX320 as its primary clinical candidate from its protease inhibitor discovery program. IDX320 is a non-covalent macrocyclic inhibitor. The company submitted a CTA for IDX320 in December 2009 and initiated a phase I healthy volunteer clinical study in January 2010.

NS5A Inhibitors

In 2009, the company has initiated an NS5A discovery program.

Licensed Products

In addition, the company has licensed its telbivudine (Tyzeka/Sebivo), a drug for the treatment of hepatitis B virus, to Novartis Pharma AG (Novartis); and GSK2248761, a drug candidate from the class of compounds known as non-nucleoside reverse transcriptase inhibitors (NNRTIs), for the treatment of human immunodeficiency virus type 1 and acquired immune deficiency syndrome to GlaxoSmithKline.

Sales and Marketing

The company, in accordance with its development and commercialization agreement with Novartis, has the right to co-promote or co-market with Novartis in the United States, United Kingdom, France, Germany, Italy and Spain any products that Novartis licenses from the company.

Competition

The company identifies competition from Abbott Laboratories; Boehringer Ingelheim International GmbH; F. Hoffman-LaRoche & Co.; Johnson & Johnson; Merck & Co., Inc.; Pfizer, Inc.; Human Genome Sciences, Inc.; InterMune, Inc.; Isis Pharmaceuticals, Inc.; Ribapharm, Inc., a wholly-owned subsidiary of Valeant Pharmaceuticals International; SciClone Pharmaceuticals, Inc.; Anadys Pharmaceuticals, Inc.; Pharmasset, Inc.; Vertex Pharmaceuticals, Inc.; and Achillion Pharmaceuticals, Inc. It also identifies competition from GlaxoSmithKline plc; Gilead Sciences, Inc.; and Bristol-Myers Squibb Company.

History

Idenix Pharmaceuticals, Inc. was founded in 1998.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. IDENIX PHARMACEUTICALS INC. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. IDENIX PHARMACEUTICALS INC. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. IDENIX PHARMACEUTICALS INC. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. IDENIX PHARMACEUTICALS INC. FINANCIAL ANALYSIS

4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. IDENIX PHARMACEUTICALS INC. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Idenix Pharmaceuticals Inc. Direct Competitors
5.2. Comparison of Idenix Pharmaceuticals Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Idenix Pharmaceuticals Inc. and Direct Competitors Stock Charts
5.4. Idenix Pharmaceuticals Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Idenix Pharmaceuticals Inc. Industry Position Analysis

6. IDENIX PHARMACEUTICALS INC. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. IDENIX PHARMACEUTICALS INC. EXPERTS REVIEW¹

7.1. Experts Consensus
7.2. Experts Revisions

8. IDENIX PHARMACEUTICALS INC. ENHANCED SWOT ANALYSIS²

9. UNITED STATES PESTEL ANALYSIS²

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. IDENIX PHARMACEUTICALS INC. IFE, EFE, IE MATRICES²

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. IDENIX PHARMACEUTICALS INC. PORTER FIVE FORCES ANALYSIS²

12. IDENIX PHARMACEUTICALS INC. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

Idenix Pharmaceuticals Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Idenix Pharmaceuticals Inc. 1-year Stock Charts
Idenix Pharmaceuticals Inc. 5-year Stock Charts
Idenix Pharmaceuticals Inc. vs. Main Indexes 1-year Stock Chart
Idenix Pharmaceuticals Inc. vs. Direct Competitors 1-year Stock Charts
Idenix Pharmaceuticals Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

List Of Tables

LIST OF TABLES

Idenix Pharmaceuticals Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Idenix Pharmaceuticals Inc. Key Executives
Idenix Pharmaceuticals Inc. Major Shareholders
Idenix Pharmaceuticals Inc. History
Idenix Pharmaceuticals Inc. Products
Revenues by Segment
Revenues by Region
Idenix Pharmaceuticals Inc. Offices and Representations
Idenix Pharmaceuticals Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Idenix Pharmaceuticals Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Idenix Pharmaceuticals Inc. Capital Market Snapshot
Idenix Pharmaceuticals Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Idenix Pharmaceuticals Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Idenix Pharmaceuticals Inc. Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

• How to use the strengths to take advantage of the opportunities?
• How to use the strengths to reduce likelihood and impact of the threats?
• How to overcome the weaknesses that obstruct taking advantage of the opportunities?
• How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

• Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
• Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
• Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
• Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
• Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
• Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

1. What composes a threat of substitute products and services?
2. Is there a threat of new competitors entering the market?
3. What is the intensity of competitive rivalry?
4. How big is the bargaining power of buyers?
5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

• Tangible resources
  • Financial
  • Physical
  • Technological
  • Organizational
• Intangible resources
  • Human
  • Innovation and Creativity
  • Reputation
• Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

• Valuable?
• Rare?
• Costly to imitate?
• Organized properly?